PCOS Diagnostic Market To Reach USD 9.81 Billion by 2032

According to a new report published by Introspective Market Research, titled, PCOS Diagnostic Market by Test Type, End User, and Region, The Global PCOS Diagnostic Market Size Was Valued at USD 5.6 Billion in 2023 and is Projected to Reach USD 9.81 Billion by 2032, Growing at a CAGR of 6%. The Polycystic Ovary Syndrome (PCOS) Diagnostic Market is witnessing robust growth due to the rising prevalence of hormonal disorders among women of reproductive age and increasing awareness regarding early diagnosis and treatment. PCOS is a complex endocrine disorder characterized by irregular menstrual cycles, excess androgen levels, and polycystic ovaries, often linked to infertility, obesity, and insulin resistance.

Advancements in diagnostic testing methods, including hormone assays, ultrasound imaging, and genetic testing, have significantly improved the accuracy and speed of PCOS detection. Increasing healthcare expenditure, growing awareness about women’s reproductive health, and the integration of digital health tools are further driving the adoption of diagnostic solutions across hospitals, fertility clinics, and diagnostic laboratories.

Furthermore, growing initiatives by healthcare organizations to promote early screening, coupled with the development of point-of-care diagnostic kits, are creating favorable conditions for market expansion. With continued research into hormonal biomarkers and personalized diagnostic approaches, the PCOS diagnostic market is expected to grow steadily through the forecast period.

A key growth driver for the PCOS Diagnostic Market is the rising incidence of lifestyle-related disorders such as obesity, insulin resistance, and diabetes, which are closely associated with the development of PCOS. The growing awareness of reproductive health and fertility issues among women, along with increased access to healthcare facilities, has led to more frequent screenings and early detection. Moreover, the inclusion of PCOS diagnosis in women’s wellness programs and government-led awareness campaigns further boosts diagnostic adoption globally.

An emerging opportunity in the PCOS Diagnostic Market lies in the integration of AI-driven imaging and biomarker-based testing. Artificial intelligence is enhancing ultrasound analysis accuracy, enabling early and precise detection of polycystic ovaries. Additionally, ongoing R&D on novel biomarkers, including anti-Müllerian hormone (AMH) and genetic indicators, offers new avenues for developing rapid, cost-effective, and non-invasive diagnostic solutions. These technological innovations, combined with telemedicine adoption, are expected to expand the market significantly in coming years.

PCOS Diagnostic Market, Segmentation

The PCOS Diagnostic Market is segmented on the basis of Test Type, End User, and Region.

Test Type

  • The Test Type segment is further classified into Blood Tests, Ultrasound Scans, Pelvic Examinations, and Other Diagnostic Tests. Among these, the Blood Tests sub-segment accounted for the highest market share in 2023. Blood tests are considered a primary diagnostic tool for evaluating hormonal imbalances such as luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and insulin levels. Their widespread accessibility, cost-effectiveness, and ability to provide detailed hormonal insights make them essential in early and accurate PCOS detection.

End User

  • The End User segment is further classified into Hospitals & Clinics, Diagnostic Centers, and Research Laboratories. Among these, Hospitals & Clinics dominated the market in 2023. This dominance is attributed to the availability of advanced diagnostic equipment, specialized gynecologists, and multidisciplinary care approaches. Hospitals also serve as primary touchpoints for women seeking fertility or metabolic evaluations, strengthening their role in PCOS diagnosis and management.

Some of the Leading/Active Market Players Are:

  • Abbott Laboratories (U.S.)
  • Siemens Healthineers AG (Germany)
  • Thermo Fisher Scientific Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Quest Diagnostics (U.S.)
  • Beckman Coulter Inc. (U.S.)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Fujifilm Holdings Corporation (Japan)
  • Mindray Medical International Limited (China)
  • PerkinElmer Inc. (U.S.)
  • Danaher Corporation (U.S.)
  • Becton, Dickinson and Company (U.S.)
  • Sysmex Corporation (Japan)
  • Merck KGaA (Germany)
  • other active players.

Key Industry Developments

  • In June 2024, Abbott Laboratories introduced an advanced hormonal biomarker panel for women’s reproductive health, enhancing early PCOS diagnosis accuracy. The new panel integrates AMH and insulin resistance indicators for a more comprehensive hormonal profile.
  • In October 2023, Siemens Healthineers launched an AI-enabled ultrasound platform to improve ovarian imaging precision in PCOS diagnosis. This innovation allows real-time follicle mapping, reducing operator variability and improving diagnostic confidence among clinicians.

Key Findings of the Study

  • Blood Tests dominated the market by test type in 2023.
  • Hospitals & Clinics accounted for the largest end-user share.
  • North America led the market in 2023, driven by advanced healthcare infrastructure.
  • Rising AI-based imaging and biomarker testing trends are shaping future diagnostics.
  • Increasing awareness programs and government initiatives continue to drive early diagnosis rates.

Share On :

Posted by  T Kumbhar

T. Kumbhar is a results-driven Senior Market Research Consultant at IMR, specializing in market trends, competitive intelligence, and data-driven insights. With extensive experience across Agrochemicals, Food Tech, Consumer Goods, Automotive, and Construction, he helps businesses make informed strategic decisions through in-depth research and analysis. His expertise includes market research, competitive analysis, business strategy, forecasting, pricing strategies, and consumer insights.